High materiality7/10
AtriCure price target lowered to $50 from $55 at UBS
Why it may matterVerify against the original reporting
Upside remains since target exceeds current price.
Public signal · 1-minute delayed
Signal brief
Source-backed market context you can read and share without an account.
AI summary
What happened, with direct paths to the underlying reporting
UBS updated ATRC price target to $50 from $55; posted price $38.47; target change -0.18% from prior.
- UBS target updated to 50; price 38.47; target change -0.18%
Key facts
- 01
Target: $50
- 02
Posted price: $38.47
- 03
Analyst firm: UBS
How to read this signal
Transparent limits for an AI-generated research aid
StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.